MERINO
2018
Piperacillin-Tazobactam vs Meropenem for ESBL Bacteraemia
In 391 patients with ceftriaxone-non-susceptible E. coli or K. pneumoniae bacteraemia, piperacillin-tazobactam increased 30-day mortality compared with meropenem.
Result
- Absolute difference
- 8.6 points
risk difference8.6P = 0.90
The absolute difference is derived from the event rates.
Also reported: For noninferiority: noninferiority not met.
- Subtopic
- ESBL bacteraemia
- Design
- Open-label non-inferiority RCT
- Relevance
- Important: one of several pillars.
- Source
- Harris PNA, et al. JAMA. 2018;320(10):984-994.doi 10.1001/jama.2018.12163
Discussion & critique
Definitive evidence to use carbapenems for ESBL bloodstream and intra-abdominal infection: piperacillin-tazobactam is not equivalent.